Igc Pharma, Inc. (IGC) intrinsic value & 10-year financials
Igc Pharma, Inc. (IGC) has a Graham intrinsic value of $1.89 per share. At $0.25 on Oct 17, 2026, the stock trades 87% below that value. Over the last 10 fiscal years revenue shrank 16.4% a year to $1.3M, with an average return on invested capital of -63.6%.
- Graham intrinsic value
- $1.89
- Share price (Oct 17, 2026)
- $0.25
- Price vs Graham value
- 87% below
- Market cap
- $18.8M
- Revenue (FY2025)
- $1.3M
- Revenue growth (10-yr CAGR)
- -16.4%
- ROIC (10-yr avg)
- -63.6%
- Free cash flow (FY2025)
- -$4.9M
IGC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.3M | -$7.1M | -$0.09 | -$4.9M | -585.8% | -119.9% |
| FY2024 | $1.3M | -$13.0M | -$0.22 | -$5.3M | -728.5% | -106.4% |
| FY2023 | $911.0K | -$11.5M | — | -$7.4M | -1270.1% | -89.1% |
| FY2022 | $289.0K | -$15.0M | — | -$7.7M | -5338.4% | -93.1% |
| FY2021 | $898.0K | -$8.8M | — | -$12.3M | -971.5% | -44.7% |
| FY2020 | $4.1M | -$7.3M | — | -$13.1M | -168.6% | -49.3% |
| FY2019 | $5.1M | -$4.1M | — | -$3.3M | -90.8% | -64.4% |
| FY2018 | $2.2M | -$1.8M | — | -$2.1M | -81.6% | -26.2% |
| FY2017 | $580.4K | -$1.9M | -$0.07 | -$1.5M | -354.0% | -20.5% |
| FY2016 | $6.4M | -$2.8M | -$0.17 | -$279.9K | -45.6% | -22.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IGC Pharma, Inc. is facing top-line stagnation, with revenue contracting over the decade.
IGC Pharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -63.6% ROIC.
Over the decade, IGC Pharma, Inc. shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, IGC Pharma, Inc. is modeled at -16.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.89 per share.